JP5389905B2 - α−７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 - Google Patents

α−７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 Download PDF

Info

Publication number
JP5389905B2
JP5389905B2 JP2011506374A JP2011506374A JP5389905B2 JP 5389905 B2 JP5389905 B2 JP 5389905B2 JP 2011506374 A JP2011506374 A JP 2011506374A JP 2011506374 A JP2011506374 A JP 2011506374A JP 5389905 B2 JP5389905 B2 JP 5389905B2
Authority
JP
Japan
Prior art keywords
mmol
methyl
amine
pyrimidinyl
octane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011506374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518831A5 (https=
JP2011518831A (ja
Inventor
ジェイムズ・エイチ・クック・ザ・セカンド
イバー・エム・マクドナルド
ダルトン・キング
リチャード・イー・ウォルソン
ネンフイ・ワン
クリスティアナ・アイ・イウアグ
クリストファー・エフ・ズシ
ジョン・イー・マコー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2011518831A publication Critical patent/JP2011518831A/ja
Publication of JP2011518831A5 publication Critical patent/JP2011518831A5/ja
Application granted granted Critical
Publication of JP5389905B2 publication Critical patent/JP5389905B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
JP2011506374A 2008-04-23 2009-04-20 α−７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 Expired - Fee Related JP5389905B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4721108P 2008-04-23 2008-04-23
US61/047,211 2008-04-23
US12/423,299 US7863291B2 (en) 2008-04-23 2009-04-14 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US12/423,299 2009-04-14
PCT/US2009/041076 WO2009131926A1 (en) 2008-04-23 2009-04-20 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands

Publications (3)

Publication Number Publication Date
JP2011518831A JP2011518831A (ja) 2011-06-30
JP2011518831A5 JP2011518831A5 (https=) 2012-05-17
JP5389905B2 true JP5389905B2 (ja) 2014-01-15

Family

ID=41215599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011506374A Expired - Fee Related JP5389905B2 (ja) 2008-04-23 2009-04-20 α−７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物

Country Status (27)

Country Link
US (1) US7863291B2 (https=)
EP (1) EP2271650B1 (https=)
JP (1) JP5389905B2 (https=)
KR (1) KR20110015565A (https=)
CN (1) CN102066384B (https=)
AR (1) AR071215A1 (https=)
AU (1) AU2009239575B2 (https=)
BR (1) BRPI0911542A2 (https=)
CA (1) CA2722325A1 (https=)
CL (1) CL2009000975A1 (https=)
CO (1) CO6300941A2 (https=)
CY (1) CY1117045T1 (https=)
DK (1) DK2271650T3 (https=)
EA (1) EA017628B1 (https=)
ES (1) ES2553753T3 (https=)
HR (1) HRP20151111T1 (https=)
HU (1) HUE028302T2 (https=)
IL (1) IL208673A (https=)
MX (1) MX2010011374A (https=)
NZ (1) NZ588649A (https=)
PE (1) PE20091977A1 (https=)
PL (1) PL2271650T3 (https=)
PT (1) PT2271650E (https=)
SI (1) SI2271650T1 (https=)
TW (1) TWI431007B (https=)
WO (1) WO2009131926A1 (https=)
ZA (1) ZA201007527B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013509405A (ja) * 2009-10-29 2013-03-14 ブリストル−マイヤーズ スクイブ カンパニー α７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8309577B2 (en) * 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
HUE025528T2 (en) 2008-04-23 2016-05-30 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
JP5693452B2 (ja) * 2008-08-04 2015-04-01 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
MX2012003126A (es) 2009-09-21 2012-06-19 Gilead Sciences Inc Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
US8278320B2 (en) 2009-10-28 2012-10-02 Bristol-Myers Squibb Company Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2011056573A1 (en) 2009-10-28 2011-05-12 Bristol-Myers Squibb Company Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
MX2012007837A (es) 2010-01-14 2012-07-30 Sanofi Sa Derivados de oxazolopirimidina 2, 5 - sustituidos.
CN103025744A (zh) * 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
ES2689103T3 (es) 2010-06-30 2018-11-08 Fujifilm Corporation Nuevo derivado de nicotinamida o sal del mismo
AU2011282241B2 (en) 2010-07-19 2015-07-30 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
AU2012322095B2 (en) 2011-10-14 2017-06-29 Ambit Biosciences Corporation Heterocyclic compounds and use thereof as modulators of type III receptor tyrosine kinases
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
US9458179B2 (en) 2012-05-24 2016-10-04 Bristol-Myers Squibb Company Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PT2970272T (pt) 2013-03-14 2019-06-05 Merck Patent Gmbh Inibidores de glicosidase
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
JP5714745B2 (ja) * 2014-04-28 2015-05-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ α７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
EP3868752A1 (en) 2014-08-28 2021-08-25 Asceneuron SA Glycosidase inhibitors
JP6564029B2 (ja) 2014-10-14 2019-08-21 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
EP3215512A1 (en) * 2014-11-04 2017-09-13 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
DK3331876T3 (da) 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc Modulators of ror-gamma
DK3785717T3 (da) 2015-09-16 2022-03-21 Gilead Sciences Inc Fremgangsmåder til behandling af coronaviridae-infektioner
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
AU2017222958B2 (en) 2016-02-25 2019-07-18 Asceneuron S. A. Glycosidase inhibitors
CN108884078A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
SG11201807012QA (en) 2016-02-25 2018-09-27 Asceneuron S A Acid addition salts of piperazine derivatives
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
EP3601259B1 (en) 2017-03-30 2022-02-23 F. Hoffmann-La Roche AG Isoquinolines as inhibitors of hpk1
EP3601235B1 (en) 2017-03-30 2026-03-04 XWPharma Ltd. Bicyclic heteroaryl derivatives, preparation and therapeutic uses thereof
CA3059777C (en) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN115650976A (zh) 2017-07-24 2023-01-31 生命医药有限责任公司 RORγ的抑制剂
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. LINEAR INHIBITORS OF GLYCOSIDASE
CN107868039A (zh) * 2017-11-27 2018-04-03 中国药科大学 一种贝曲沙班中间体n－（5－氯－2－吡啶基）－2－［（4－氰基苯甲酰基）氨基］－5－甲氧基苯甲酰胺的制备方法
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039027A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Pyrrolidine glycosidase inhibitors
IL280841B2 (en) 2018-08-22 2024-12-01 Asceneuron S A Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021039968A1 (ja) 2019-08-30 2021-03-04 大日本住友製薬株式会社 ２－アミノキナゾリノン誘導体
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808433D0 (en) * 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
US5053412A (en) 1990-04-10 1991-10-01 Israel Institute For Biological Research Spiro nitrogen-bridged heterocyclic compounds
IL97726A (en) 1990-04-10 1994-12-29 Israel Inst Biolog Res Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
ATE192157T1 (de) * 1994-08-24 2000-05-15 Astra Ab Therapeutisch verwendbare spiro-azabicyclische verbindungen
AU2003223093B2 (en) * 2002-05-03 2010-02-04 Israel Institute For Biological Research Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
CN1829721A (zh) 2003-07-08 2006-09-06 阿斯利康(瑞典)有限公司 对α7烟碱乙酰胆碱受体具有亲和力的螺[1－氮杂二环[2.2.2]辛烷－3,5’－噁唑烷]－2’－酮衍生物
MX2007006743A (es) 2004-12-15 2007-07-09 Astrazeneca Ab Ligandos del receptor de acetilcolina nicotinica.
US20070004715A1 (en) 2005-06-30 2007-01-04 Yifang Huang Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders
ITMI20061279A1 (it) 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche
US8309577B2 (en) * 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013509405A (ja) * 2009-10-29 2013-03-14 ブリストル−マイヤーズ スクイブ カンパニー α７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物

Also Published As

Publication number Publication date
CN102066384B (zh) 2014-07-30
IL208673A0 (en) 2010-12-30
TWI431007B (zh) 2014-03-21
PL2271650T3 (pl) 2016-03-31
CN102066384A (zh) 2011-05-18
EP2271650B1 (en) 2015-09-16
SI2271650T1 (sl) 2015-12-31
WO2009131926A1 (en) 2009-10-29
EP2271650A1 (en) 2011-01-12
IL208673A (en) 2013-09-30
BRPI0911542A2 (pt) 2015-10-13
ZA201007527B (en) 2012-03-28
CA2722325A1 (en) 2009-10-29
EA017628B1 (ru) 2013-01-30
CL2009000975A1 (es) 2011-02-18
AR071215A1 (es) 2010-06-02
MX2010011374A (es) 2010-11-12
EA201001696A1 (ru) 2011-06-30
PT2271650E (pt) 2015-12-01
KR20110015565A (ko) 2011-02-16
NZ588649A (en) 2012-05-25
AU2009239575A1 (en) 2009-10-29
ES2553753T3 (es) 2015-12-11
TW200948812A (en) 2009-12-01
CO6300941A2 (es) 2011-07-21
HUE028302T2 (en) 2016-12-28
DK2271650T3 (en) 2015-12-21
HRP20151111T1 (hr) 2015-12-18
AU2009239575B2 (en) 2014-02-20
US20090270405A1 (en) 2009-10-29
PE20091977A1 (es) 2010-01-15
JP2011518831A (ja) 2011-06-30
US7863291B2 (en) 2011-01-04
CY1117045T1 (el) 2017-04-05

Similar Documents

Publication Publication Date Title
JP5389905B2 (ja) α−７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物
US8309577B2 (en) Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
JP2018521025A (ja) Ｔｎｆ活性のモジュレーターとしてのベンゾオキサジノン誘導体およびその類似体
JP5619907B2 (ja) α７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物
EP2855471B1 (en) QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
JP2013509413A (ja) α７ニコチン性アセチルコリン受容体リガンドとしてのアザビシクロ［２．２．１］ヘプタン化合物
JP5714745B2 (ja) α７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131009

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees